
Repare Therapeutics (RPTX) Stock Forecast & Price Target
Repare Therapeutics (RPTX) Analyst Ratings
Bulls say
Repare Therapeutics Inc. has demonstrated promising advancements in precision oncology, particularly with the favorable tolerability of its camonsertib + lunresertib combination therapy, which has shown a significant reduction in anemia rates through individualized schedule optimization. The company’s ACR-2316, a dual Wee1/Myt1 inhibitor, has outperformed competitor therapies in reducing tumor volume across various models, highlighting its strong potential in clinical applications. Furthermore, the incorporation of risk-adjusted revenue projections for the promising RP-3467 therapy, alongside positive preclinical outcomes, underpins a positive outlook on the company's future financial performance.
Bears say
Repare Therapeutics Inc. faces significant risks that contribute to a negative outlook on its stock, including the potential for negative data from key proof-of-concept trials, which could hinder the advancement of their drug candidates into later-stage trials. Additionally, the company may encounter challenges in obtaining regulatory approval for its agents, along with partnership risks that could hinder strategic collaborations essential for development. Compounding these issues are concerns regarding the slower-than-anticipated market uptake for its therapies due to pricing challenges and competitive pressures, alongside the risk of long-term dilution for existing shareholders.
This aggregate rating is based on analysts' research of Repare Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Repare Therapeutics (RPTX) Analyst Forecast & Price Prediction
Start investing in Repare Therapeutics (RPTX)
Order type
Buy in
Order amount
Est. shares
0 shares